TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance

[1]  B. Monk,et al.  Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Benjamin G. Bitler,et al.  The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity , 2021, Cancer Immunology Research.

[3]  Yihui Fan,et al.  The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation , 2021, Acta pharmaceutica Sinica. B.

[4]  Wei Zhao,et al.  TRIM28 SUMOylates and stabilizes NLRP3 to facilitate inflammasome activation , 2021, Nature Communications.

[5]  Q. Cheng,et al.  Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer , 2021, Journal of experimental & clinical cancer research : CR.

[6]  T. Mempel,et al.  Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop , 2021, Cell.

[7]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[8]  Daniel J. Freeman,et al.  Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells. , 2021, Cancer discovery.

[9]  J. Ji,et al.  Gastric cancer: Epidemiology, risk factors and prevention strategies , 2020, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[10]  Jun Xie,et al.  Immunotherapy of gastric cancer: Past, future perspective and challenges. , 2020, Pathology, research and practice.

[11]  Jinfang Zhang,et al.  Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1 , 2020, Cell Death & Differentiation.

[12]  J. K. Yun,et al.  Sequential ubiquitination of p53 by TRIM28, RLIM, and MDM2 in lung tumorigenesis , 2020, Cell Death & Differentiation.

[13]  Clifford A. Meyer,et al.  In Vivo CRISPR Screens Identify E3 Ligase Cop1 as a Modulator of Macrophage Infiltration and Cancer Immunotherapy Target , 2020, bioRxiv.

[14]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[15]  D. Geller,et al.  Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells , 2020, Cancer Immunology, Immunotherapy.

[16]  G. Mills,et al.  Verteporfin Inhibits PD-L1 through Autophagy and the STAT1–IRF1–TRIM28 Signaling Axis, Exerting Antitumor Efficacy , 2020, Cancer Immunology Research.

[17]  P. Robbins,et al.  Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment , 2020, Diagnostic Pathology.

[18]  C. Qin,et al.  The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein , 2019, Cell Death & Differentiation.

[19]  Xuhong Cheng,et al.  TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis , 2019, Nature Cell Biology.

[20]  Shao-Cong Sun,et al.  TBKBP1 and TBK1 form a growth factor signaling axis mediating immunosuppression and tumorigenesis , 2019, Nature Cell Biology.

[21]  A. Rotte,et al.  Combination of CTLA-4 and PD-1 blockers for treatment of cancer , 2019, Journal of experimental & clinical cancer research : CR.

[22]  M. Hung,et al.  MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. , 2019, Gastroenterology.

[23]  J. Spicer,et al.  Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma , 2019, Front. Immunol..

[24]  T. Pan,et al.  TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb , 2019, eLife.

[25]  Jinfang Zhang,et al.  Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. , 2018, Trends in biochemical sciences.

[26]  M. Hung,et al.  Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. , 2018, Cancer research.

[27]  Jindan Yu,et al.  TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression , 2018, Nature Communications.

[28]  L. Fashoyin-Aje,et al.  FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1 , 2018, The oncologist.

[29]  Y. Zhang,et al.  TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1–TSC2 complex , 2018, Oncogene.

[30]  Patrycja Czerwińska,et al.  The complexity of TRIM28 contribution to cancer , 2017, Journal of Biomedical Science.

[31]  S. Dawson,et al.  CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity , 2017, Nature.

[32]  Feng Zhang,et al.  Identification of essential genes for cancer immunotherapy , 2017, Nature.

[33]  H. Horlings,et al.  Identification of CMTM6 and CMTM4 as PD-L1 protein regulators , 2017, Nature.

[34]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[35]  Eric S. Lander,et al.  Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras , 2017, Cell.

[36]  G. Hortobagyi,et al.  Deubiquitination and Stabilization of PD-L1 by CSN5. , 2016, Cancer cell.

[37]  V. Boussiotis.  Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. , 2016, The New England journal of medicine.

[38]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[39]  Jun S. Liu,et al.  Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR , 2015, Genome Biology.

[40]  D. Durocher,et al.  High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities , 2015, Cell.

[41]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[42]  D. Trono,et al.  TRIM28 Represses Transcription of Endogenous Retroviruses in Neural Progenitor Cells , 2014, Cell reports.

[43]  Jun S. Liu,et al.  MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.

[44]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[45]  John H. White,et al.  Ligand-dependent corepressor contributes to transcriptional repression by C2H2 zinc-finger transcription factor ZBRK1 through association with KRAB-associated protein-1 , 2014, Nucleic acids research.

[46]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[47]  Ming-Ming Zhou,et al.  PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. , 2007, Molecular cell.